Gufic Biosciences Ltd. (BSE: 509079) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹4,043 Cr, it ranks #932 by market cap among the 6,137 Indian listed companies on FinBizNet, and #30 of 86 in Medicinal Chemicals and Botanical Products. At ₹391.80 (as of 25 Oct 2026), the share price is 16.2% below its 52-week high of ₹467.80 and 46.2% above its 52-week low of ₹268.00. The share price is up 10.3% over one year and up 3.4% over three months.
| Current Price | ₹391.80 |
|---|---|
| Market Cap | ₹4,043 Cr |
| BSE Code | 509079 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 63.4 |
| Return on Equity | 10.14% |
| Return on Assets | 6.00% |
| 52-Week Range | ₹268.00 – ₹467.80 |
| 1-Year Price Change | +10.3% |
| 3-Month Price Change | +3.4% |
| Beta (1Y) | 0.07 |
| Dividend Yield | 0.02% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.gufic.com |
| Revenue | ₹261 Cr |
|---|---|
| Net Profit | ₹22 Cr |
| Net Margin | 8.6% |
| EPS (Basic) | ₹2.22 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America. The company manufactures APIs and bulk drugs, such as antifungals, anaethetics, immuno suppressants, anginotensin receptor blocker, and intermediates for antifungals. It also manufactures lyophilized injections for antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs) segments. In addition, the company offers criti care, criticare life, ferticare, and spark pharmaceutical products; and herbal, aesthaderm, gufic stridden, and personal care products. Further, it engages in contract and bulk drug manufacturing business. Gufic Biosciences Limited was founded in 1970 and is based in Mumbai, India.
1. Pharmaceutical and Related Products-This segment engages in the manufacture and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. 2. Pharma-This segment manufactures and trades in tablets, capsules, ointment, syrups/suspension products, powders, injections and lotions, etc. 3. Bulk Drug-This segment manufactures medicinal chemicals. 4. Unallocable Overheads-0
1. Pharmaceutical and Related Products-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Gufic Biosciences Ltd. | ₹4,043 Cr | 63.4 | 10.14% | ₹261 Cr | +10.3% |
Listed by market capitalisation. Ratios are shown for context only.
Gufic Biosciences Ltd. is trading at ₹391.80, with a market capitalisation of ₹4,043 Cr.
Gufic Biosciences Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Gufic Biosciences Ltd. has a P/E of 63.4 and a return on equity of 10.14%.
Gufic Biosciences Ltd. is listed on the BSE under the scrip code 509079.
Gufic Biosciences Ltd.'s share price is up 10.3% over one year and up 3.4% over three months. Its 52-week range is ₹268.00 to ₹467.80.
In Q1 FY27, Gufic Biosciences Ltd. reported revenue of ₹261 Cr and net profit of ₹22 Cr, with basic EPS of ₹2.22 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.